The association between reproductive factors and neurocognitive and neuroimaging markers of brain aging
BackgroundWomen have a higher risk of dementia than men. Reproductive factors may be implicated.ObjectiveDetermine the association between reproductive factors (earlier menarche, later menopause, longer reproductive lifespan (RLS), post-menopausal hormone replacement therapy [pmHRT] use, and serum estradiol/estrone) and neurocognitive and neuroimaging markers of brain aging and incident dementia in cognitively healthy women.MethodsLifetime reproductive factors were measured in dementia-free women [mean age 60.3 (SD 9.3) year] from the Framingham Heart Study Offspring cohort between 1998-2001 and related to concurrent neurocognitive (n = 1329) and MRI brain measures (n = 1165) using multivariable linear regression and risk of incident dementia (secondary outcome, n = 921) using Cox proportional hazards regression.ResultsUse of pmHRT (Beta (β, standardized regression coefficient)±standard error (SE), 0.14 ± 0.05, p = 0.009), elevated serum estradiol (0.06 ± 0.03, p = 0.02) and earlier menarche (≥14 years versus 12-13 years, -0.13 ± 0.06, p = 0.03) were associated with better abstract reasoning (Similarities). Older age at menopause (≥52 years versus the referent 50-51 years) (0.18 ± 0.09, p = 0.04), elevated serum estradiol (0.06 ± 0.03, p = 0.02), and 1-2 (0.17 ± 0.08, p = 0.03) or ≥3 (0.22 ± 0.08, p = 0.007) versus no live births were associated with superior visuospatial performance (Hooper's visual organization test). Earlier menopause age was associated with lower hippocampal volume (≤49 years versus 50-51 years, -0.11 ± 0.04, p = 0.02) while 1-2 (5.50 ± 1.95, p = 0.005) and ≥3 live births (β±SE, 4.94 ± 1.96, p = 0.01) were associated with greater total cerebral brain volume.ConclusionsIn general, greater exposure to estrogen throughout a woman's reproductive lifespan was associated with enhanced cognitive performance and larger brain volumes. Our results may suggest positive cognitive benefits of greater lifetime estrogen exposure, but require further validation.
Authors
- Ramachandran Srini Vasan (ORCID: https://orcid.org/0000-0001-7357-5970)
- Sudha S. Seshadri (ORCID: https://orcid.org/0000-0001-6135-2622)
- Matthew R. Scott (ORCID: https://orcid.org/0000-0003-1404-4437)
- Rachel F. Buckley (ORCID: https://orcid.org/0000-0002-5356-5537)
- Emer R. McGrath (ORCID: https://orcid.org/0000-0002-3589-2964)
- Joanne M. Murabito (ORCID: https://orcid.org/0000-0002-0192-7516)
- Alexa S. Beiser (ORCID: https://orcid.org/0000-0001-8551-7778)
- Shalender Bhasin M. D (ORCID: https://orcid.org/0000-0002-3982-6200)
- Charles DeCarli (ORCID: https://orcid.org/0000-0003-1914-2693)
- Amy Werry
- Saptaparni Ghosh (ORCID: https://orcid.org/0009-0009-6280-1624)
- Claudia Liliana Satizábal (ORCID: https://orcid.org/0000-0002-1115-4430)
Institutions
- Boston University (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- The University of Texas at San Antonio Health Science Center (US)
- Ollscoil na Gaillimhe – University of Galway (IE)
- Florey Institute of Neuroscience and Mental Health (AU)
- Massachusetts General Hospital (US)
- Institute for Neurodegenerative Disorders (US)
- The University of Texas at San Antonio (US)
- University of California, Davis (US)
Publication Details
- Journal
- Journal of Alzheimer s Disease
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1177/13872877251372430
- Primary Topic
- Menopause: Health Impacts and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00